Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus high-dose oral ferrous succinate with roxadustat in maintenance hemodialysis renal anemia
ChiCTR2300072926Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferrous succinate and roxadustat in anemia of chronic kidney disease (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Mean change in hemoglobin from baseline to end of treatment and Percentage of hemoglobin below 90 g/L. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
ferrous succinateroxadustat
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on ChiCTR2300072926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072926.